James Quigley
Analyst, Goldman Sachs
Replay available
Merck KGaA (Xetra:MRK) Q3 2026 earnings call, held 2026-11-12. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/merck-kgaa-mkgaf-q3-2026-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on Perth Quarter 2026. As a reminder, all participants will be in listen-only mode. I am now handing over to Florian Schraeder, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.
0:20 Thank you very much, Madalena. Good afternoon, good morning, everyone, and welcome to our Q3 2026 results call. Thank you for joining us today. My name is Florian Schraeder and I'm the Head of Investor Relations at Merck. In today's call, Kai Beckmann, Group CEO, will open with an update on the steps taken over the course of the summer that are linked to our new strategic direction. He will then highlight our third quarter business performance and key developments in his executive summary. Helene von Roeder, Group CFO, will present the financial overview in more detail. Before we turn to your questions, Kai will share our updated outlook and guidance. Jean Charles Wirth, CEO of LifeScience, Danny Bar-Zohar, CEO of Healthcare, and Benjamin Hein, CEO of Electronics, will join us for the Q&A.
1:12 And now, I'm delighted to hand over to Kai to get us started.
1:17 Thank you, Florian, and good afternoon, good morning, and thank you all for being with us today. And let's get started now. So first let me provide an update on our strategic direction, which we announced in May and which we detailed today. So as you know, it rests on four streams. Focus on high-growth value drivers, shifting selected product portfolios towards integrated workflows, connecting and leveraging our platform capabilities across our business, and scale and source innovation via M&A and in-licensing. So we further defined our approach on high-growth value drivers which we define as sizeable, fast-growing end-market segments where we want to continue strengthening our position. We identified four segments, biomanufacturing, discovery and development across the life sciences value chain, semiconductor manufacturing that supports AI and advanced nodes, as well as targeted specialty and rare diseases.
2:15 So speaking of rare diseases, I trust that you have seen the positive news on Tuesday, the FDA approved in Germany which is our brand name for Pimicotinib as a systemic treatment for patients with symptomatic tenosynovial giant cell tumors. This is an important milestone in our way to further expand the reach of our rare diseases franchise. Our growth depends on more than investments in M&A. It also depends on how well we execute. And when we look at our strategic direction alongside our results over recent quarters, we can see how the pieces fall into place. And with that, let's move on to the next slide to discuss the highlights of the quarter. I think it's fair to say that the third quarter delivered solid results and that we have continued to advance our strategic priorities across the business in the last few months.
3:08 And as you know, earlier this year, we set out where we see the strongest opportunities to grow. This quarter, we took further steps in that direction and worked to better address the needs of our patients and customers. Before we get to the numbers, I'd like to highlight a few developments that show how we are putting our strategic direction into action. Together, they reflect three themes. Strengthening our capabilities, sharpening our portfolio, investing in our global footprint. In October, we announced the planned acquisition of Silent Therapeutics, which is a strategically important step toward strengthening our mid-stage pipeline, and if completed, it would add The acquisition is in line with our focus on targeted specialty and rare diseases.
4:00 We also see it as an opportunity for future expansion into hematology. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions. At the same time, our strategic agenda is also about making choices and sharpening our portfolio. Therefore, we announced the planned divestment of our CDMO business to Lonta last week. This is another important step in advancing our mid- to long-term strategic agenda. It allows us to reduce capital intensity and further focus our portfolio on businesses with strong value creation. The transaction is expected to close in mid-2027, subject to regulatory approvals and closing conditions.
4:48 Finally, I am pleased to share that we are only a few steps away from closing the biotechnology acquisition. This important milestone could bring world-class R&D and innovation that will support growth in life sciences discovery and development. In our investor call on June 25th, we shared our expectation that the inclusion of biotechnology should be immediately accretive to sales growth and margins, and we expect a contribution still this year, while the actual closing date of the transaction is not set yet. I will share details in our guidance update in a few minutes. In parallel to portfolio choices, we are investing in our global footprint, with side openings in Dijon, Sheboygan and Darmstadt.
5:35 South Korea, our new Asia-Pacific bioprocessing is now officially open. With investment of more than 300 million euros, the center strengthens our in-region, for-region commitment in Asia-Pacific and globally. It also supports South Korea's growing role as a regional hub for biopharmaceutical manufacturing. In Sheboygan, Wisconsin, we opened a new 38,000 Thank you very much. This brings these services closer to biopharmaceutical customers across the region.
6:40 With that, let me now turn to a summary of financial performance in the third quarter. Following a strong first half of 2026, we sustained our growth momentum in the third quarter. Organic sales growth accelerated to 5.1% with significant contributions from life science and electronics. Healthcare sales also improved sequentially despite ongoing headwinds. Lifesigns delivered across all regions, process solutions again performed strongly with organic sales growth of 10.5%. Advanced solutions continued to achieve solid growth while discovery solutions recorded modest growth supported by stabilizing markets.
7:27 In healthcare, all franchises except specialty care contributed to broadly stable sales. The rare diseases portfolio made its first contribution to organic growth with growth in the mid-double-digit percentage range. Cardiometabolic as well as fertility and endocrinology each achieved mid-single-digit growth. Advance in specialty care became more pronounced as the loss of excessivity for maven blood in the U.S. accelerated sales erosion in Q3. In electronics, organic growth accelerated visibly reaching 13% in the third quarter. Semiconductor solutions grew strongly with organic sales up 19% supported by continued momentum in advanced nodes.
8:12 Optronics was broadly stable while headwinds in consumer electronics and markets are expected to intensify further. Overall, we achieved our ambition of profitable organic growth for the group by continuing to invest in innovation. The year-over-year comparison for epithelial pre-growth was effected by material one-off effects in Q3 2025. Helene will share further details on this later. Another highlight was the strong cash generation, which further improved our leverage ratio ahead of the expected closing of the biotechnology acquisitions. On the strength of these results, we raised our full-year guidance once again. I will provide the details later in this course.
9:00 Let's take a closer look at the growth composition for sales in EBITDA3, now on page 7. This quarter, the combined effect of organic growth, foreign exchange rates, and portfolio changes were more favorable compared to H1, contributing to an acceleration in growth momentum. Year-over-year, reported net sales growth of 5.8% in Q3 was 240 basis points higher than the reported growth rate of 3.4% in Q2. Organic sales growth was 100 basis points higher at a rate of 5.1% after 4.1% in Q2. Foreign exchange effects shifted from negative in the first half to positive in Q3, contributing 1.5 percentage points. Portfolio effects had a slightly negative impact of 0.8 percentage points.
9:52 Organic EBITDA pre-growth of 0.4% held up Well, despite having a net double-digit million lower one-off support versus Q3 2025. I now hand over to Helene, who will share further details.
10:07 Thank you very much, Kai, and a warm welcome from my side. Let's take a closer look at the details of the financial performance in the third quarter. Looking first at reported growth and the key metrics on slide 9. As Kai did already point out, the mix shifted considerably from Q2. All in all, very much in our favor. As you are all aware, reported leveraged growth and strong cash generation, regardless of whether growth is organic or external, will gain in importance in the coming year. In that context, let me comment on biotechnology and the anticipated sale of the CDMO business. We expect biotechne to add a portfolio effect of close to 5% to group reported sales growth and about 10% to life science reported sales growth in 2027.
10:59 We will quantify the CDMO-related effect more precisely after the closing which we expect next year. Both biotechne and the CDMO sale are expected to be immediately accretive to group and life science EBITDA pre-margins after closing. So returning to Q3, EBITDA pre increased by 0.8%. The Q3 2025 comparison benefited from a 60 million gain of the sale of a priority review voucher and a further 59 million euro tailwind from legislative changes in South America. EPS pre was unchanged year over year in Q3. A lower negative financial result was offset by higher depreciation and amortization.
11:46 Reported EPS were affected by an impairment related to the sale of the CDMO business, which also drove our calculated tax rate to 23.9% in Q3, resulting in a rate of 23.2% year-to-date. And here's one housekeeping item. As of 2027, we expect our underlying tax rate to be in the range of 22 to 24%, which is one percentage point higher than the range of the past years. Now that mainly reflects a shift in the geographic mix of our profits. Softer demand for certain healthcare products, manufactured in Switzerland, is reducing Switzerland's relative contribution to group profit over time.
12:31 And that is increasing the weight of profits in higher tax jurisdictions. With that, let's turn to the financial performance by business sector. And I'm starting with life science on slide 10. Sales grew organically by 6.1% year over year, excluding the impact of tariff refunds to customers. Growth would have been 7.3%. It was again process solutions who led the growth, increasing by 10.5%, including tariff-related headwinds. Underlying growth was 12.6%, driven by customer projects and downstreams. Unlike in the first half of 2026, growth was not boosted by extraordinary effects. While the underlying demand and customer capacity expansion remained strong, you may recall that we talked in August about order book trends, which pointed to a softer fourth quarter.
13:31 Despite challenging environment, Discovery Solutions delivered organic sales growth of 1.7% or 2.4% excluding customer refunds. Overall, academia was stabilizing, but still with very different regional patterns. We also saw greater strength in the business with customers in the industry and testing segment. Advanced solutions continue to perform solidly with organic growth of 4.3%. The main growth drivers here were CDMO, biomonitoring, and lab water. Here, all regions out of China grew. led by the Americas and the rest of Asia-Pacific. Sales in China were only slightly below the prior year.
14:16 Now to address the question you may have already now. The CDMO assets which we agreed to sell to Lonza accounted for less than 10% of Q3 sales in Advanced Solutions. The related EBITDA pre-margin was below the Lifesign sectors margin. This provides context for my earlier comment about the expected margin accretion following the closing. Also, let me close the discussion on tariffs here. With the completion of Q3, we have recognized all tariff-related effects. The total top-line impact, year-to-date, amounted to 35 million euros, of which 26 million euros was recognized in Q3. LifeSense EBITDA Pre grew by 8.7%, primarily driven by volume growth and process solutions, and supported by tariff refunds received.
15:10 These contributions were partly offset by higher R&D investments and capacity expansion. Now let's look at healthcare, and we're with that on slide 11. Growth in rare disease, cardiometabolic, as well as fertility and endocrinology were offset Our rare disease portfolio continued advancing. Q3 was the first quarter in which it contributed to organic growth. Oxidio and Gomiclis delivered strong year-over-year growth of 25% and 80% respectively. In Q4, we may see the usual year-end stocking effects. That said, we will continue working to accelerate the underlying uptake in the US and other regions going forward.
16:00 Fertility and endocrinology return to organic growth. The prior year U.S. price effect for Gonal-F has largely annualized, and both Pergoveris and Sizen grew in the double-digit percentages. Marventlad again showed double-digit growth in Europe, while erosion in the U.S. accelerated in Q3. Our updated 2026 guidance continues to reflect only what has been booked in terms of U.S. sales to date. Growth of Erbitrox once again mitigated the decline in specialty care supported by the breakwater regimen. EBITDA pre-benefited from strong cost discipline and sequentially stable R&D expense, offsetting margin pressure related to lower Maventat sales.
16:49 Given the expected continuing erosion of Maventat sales in the US, as well as launch preparations and the expansion of Phase 3 projects, We expect the EBITDA pre-margin to decline from here. However, achieving a margin north of 30% remains paramount to us also in the future. This also holds true in light of potential effects related to a Phase III start for Divergeron following the expected closing of the acquisition of Silent Therapeutics in Q1 of next year. Let's move on to electronics. The electronics business sector accelerated its growth yet again in Q3. Organic growth of 13% was broad-based across all key regions with strong momentum in the ramp-up of advanced nodes across logic and memory supported by AI demand.
17:44 All part of the semiconductor solutions portfolio contributed to a very strong organic growth of 19%. Alongside strong volume growth and favorable mix, Sales benefited from price adjustments associated to higher raw material prices. We view this additional contribution as temporary and expected to fade as market conditions normalize over the course of 2027. Optronics remained around stable. However, let me reiterate what I said in August. The business continues to face headwinds from softer demand for consumer electronics influenced by higher memory prices. and we continue to assume that this could result in a more pronounced year-over-year decline of net sales in Q4.
18:32 Bottom line. We saw a strong underlying performance of the electronics business in Q3, including significant operating leverage. It was a clean quarter without material one-off effects. EBITDA pre-increased organically by more than 17% to 279 million euros. The Q3 margin of 29.5% demonstrates further progress in our operating performance. Looking ahead, we continue to see scope for further gradual improvement in our underlying EBITDA margin, supported by volumes, mix, and cost discipline. A few words on key development in our balance sheet, which reflects the effect of the portfolio measures we plan to execute in the coming months.
19:21 Total assets stood at 53.7 billion euros at the end of September, up from 51.5 billion euros in December last year and 52.7 billion euros in June. Cash and cash equivalents increased in anticipation of the upcoming payment for the biotechnology acquisition. The main drivers here were strong underlying free cash flow and the liquidation of short-term investments. The year-to-date increases in receivables and inventories reflect the expansion of the business. However, receivables remain stable sequentially despite further growth thanks to improved cash collection processes. Inventories declined quarter on quarter despite continued strong growth in life science and electronics.
20:07 The increase in other assets was related to the recognition of CDMO assets held for sale, biotechnology hedging measures, and equity investments. On the equity and liability side, our equity ratio increased to 59% up from 57% in Q2, driven by earnings growth and favorable foreign exchange effects. Financial debt remained stable, while other liabilities declined following a change in the discount rate used to calculate pension provision. Now to round off my remarks, I would like to highlight a few cash flow developments which are particularly important to me, as leverage growth also needs to translate in higher cash generation as the second level of value creation.
20:55 Solid growth and sequentially stable working capital drove high single-digit growth in operating cash flow, reducing net debt and the leverage ratio as Kai already noted earlier. Operating cash flow rose by almost 10% to 1.66 billion euros in Q3 compared with 1.5 billion euros in the same quarter of last year. The starting point in the table on slide 14 reported profit after tax declined primarily due to the impairment of the CDMO assets held for sale, which at the same time triggered the significant increase of DNA. Within net working capital, lower trade payables affected cash flow negatively, while receivables management and inventory levels developed favorably.
21:43 Underlying cash generation has strengthened noticeably in recent months. Maintaining that progress will remain a priority as we work to leverage rapidly following the plant acquisition of biotechnics. You may recall that we predicted in June that the leverage ratio post-closing should be below three times net debt to EBITDA pre. It now appears possible that we will end the year clearly below that level. Cash used in investing activity decreased, reflecting disciplined spending and the completion of several larger investment projects. The main driver, however, was the liquidation of financial investments ahead of the expected closing of biotechnology acquisitions. Financing cash flow reflected the repayment of a hybrid bond.
22:29 And with that, I will hand back to Kai.
22:33 Thank you, Helene. It's a pleasure to share for the third time an upgraded full year 2026 guidance. Let me guide you through the details on slide 16 and 17. We now expect Organic growth in group net sales of 3-4%, compared with 1-3% previously. We saw easing headwinds from foreign exchange rate in Q2, which has become a tailwind in Q3. The foreign exchange impact now is expected to amount to minus 1-0% after minus 2-0% previously. Hence, group net sales are expected to reach around 21.5-21.9 billion euros. versus our previous net sales guidance of 21 to 21.8 billion euros.
23:18 Apart from improvements in the underlying performance and more favorable FX effects, we now also account for contribution from Biotechni as an additional portfolio effect for the month of December. For Group EBITDA Pre, we now expect 6.2 to 6.4 billion euros compared with 5.9 to 6.3 billion euros previously. This reflects an organic growth of 3-5% compared with 0-3% before. EPS3 is expected to be in the range of €8.30 to €8.70, a 3% increase compared to the previous range of €7.90 to €8.60. So let's look into the business sector guidance. We raised once again the lower end of our sales growth guidance for Lifetime.
24:07 The new organic sales growth range is now expected between 6% and 7% versus 5% to 7% in August. The midpoint of the guidance in absolute numbers moves up to 9.5 billion euros. In addition, this forecast reflects the acquisition of Biotechni in the month of December as a portfolio effect on sales of the life science business sector. This is an assumption. The actual closing date of the transaction may differ. Based on this assumption, the portfolio effect would result in a high double-digit million contribution for life science in 2026. The beta pre-organic growth in life science is now expected in a range of 6-8% compared with 5-8% previously. The midpoint of the range in absolute numbers increases from 2.7 billion euros to 2.8 billion euros.
24:58 For healthcare, we now expect organic net sales development of minus 2% compared with minus 4% to minus 2% in August. This is proven by our assumptions on Maven Flat US, now assuming zero sales as of November, as slightly better performance in other parts of the business. EBITDA-3 in healthcare is expected to be around 2.9 to 3 billion euros compared with 2.8 to 3 billion euros previously. For electronics, we raised Our organic net sales growth guidance once again now to 10 to 11 percent from 6 to 9 percent previously. EBITDA pre for electronics is now expected to be around 1.1 billion euros after 1 billion euros in August. The respective range for organic EBITDA pre growth moves from 25 to 29 percent to 33 to 35 percent, reflecting the operating leverage in semi-solutions but also Thank you Kai.
25:56 Before we open the lines for the Q&A, one final announcement. We would like to invite you to our ESG investor update call on December the 8th
26:24 This 90-minute virtual session will give sustainability-focused investors and analysts the opportunity to hear from our top management about our ESG priorities and how they support long-term value creation. And with that, I will ask Madalena to open the Q&A session. Thank you. We will now begin our question and answer session. If you have a question for our speakers, please dial star 11 on your telephone keypad now to enter the queue. Once your name has been announced, you can ask a question. If you are using speaker equipment today, please lift the handset before making your selection. One moment please for the first question.
27:15 The first question for today comes from Richard Foster from JP Morgan. Please go ahead.
27:22 Hi, thanks for taking my questions. Two, please. First question just on process solutions. Maybe you could give us a little bit more color what you're seeing talking to customers that has led to also what you're seeing in the order book, what's led to how you're seeing Q4 develop, and maybe you could give us a little bit of color how you're thinking about next year as well on process solutions. And then second question, just on Pergoveris in the US, we've seen Some potential news today about the FDA maybe abandoning the CMPV process and having that wound down. Maybe you could give us an update on how that review is going, how we should think about this as a potential opportunity for sales growth in the IN27 for the healthcare part of the business.
28:13 Thanks very much. Thank you, Richard. Jean Charles speaking. Let me answer the first question concerning process solution, but Maybe before I go and process, I would like to zoom out and give you a kind of sense about our Q3 performance for total last science. So, Q3 was a solid quarter for last science, with, as mentioned, an organ growth of 6.1%, and excluding tariff refund to customer, the underlying growth would have been 7.3%. Something important to mention is We have a clean quarter with no special effects, except only this item around the tariff reference customer.
28:58 When you peel the onion, very solid performance in advanced solutions for 0.3% organically. I would say Discovery Solutions 1.7% organic growth, we are pleased. And now let me zoom into your question on process solutions. So process solutions deliver... A 10.5% organic growth year-over-year in Q3 and adjusted again from the effects related to the tariff refund, the growth will have been 12.6%. And we are seeing positive momentum across process solutions, namely in downstream, in upstream and single use. All franchises posted a positive organic growth this quarter.
29:46 So, when you look year-to-date September, I would say Process Solution is having a very strong sales growth. And talking about year-to-date performance, I would like to mention as well that the book-to-bill ratio of Process Solution year-to-date September is above 1. Now, talking about Q4 for Process Solution, we expect to have an organic growth around mean single digits. Thank you very much. For your question on 2027, you should understand that we do not provide guidance.
31:01 The one thing that we should all agree is on our comps. Our comps in H1 2027 will be much higher and we should see an easier comp in H2. So if you zoom out and take a look at mid-term guidance starting in 2026, we confidently consume a mid-term outlook of 8 to 12% organic growth in the range for process solution in 2027.
31:39 Hi Richard, it's Danny. Regarding Pergoveris, so in the same spirit, let's also zoom out a little bit regarding the geographical expansion of Pergoveris. In March, we launched Pergoveris in China, in the private market, and we are working towards inclusion in NRDL, and as of now, we chose quite encouraging signs in China. But we have a question for the United States. So, in short, nothing has materially changed since what I said and also the tone that I used in the last call. We are still under review. We are collaborating with the FDA, and we are expecting a decision in the coming months. You made a comment regarding the CNPV.
32:28 Of course, we hold this CNPV. It is not expired. We filed. The file was accepted. On paper, formally, it can take more months for the FDA to complete the review, and we will, of course, update you if we know something material. In the meantime, we are preparing for a potential launch, as we said already in previous calls.
32:59 Thank you very much. Thank you. We are now going to take the next question. And this one is from Peter Veldult from BNP Paribas. Please go ahead.
33:15 Yeah, thanks, Peter Veldult, BNP Paribas. Two questions. Firstly, for Ben, can you help ballpark quanticide a volume price mix behind the 19% semi-solutions growth? Thank you very much. could be a year where you trend above your mid-term target of 7% to 11% for semi-solutions. And then more quickly and broadly for Kai or Helene, the market's penciling around 4% to 5% organic growth for next year. Totally understand this is not a guidance call for next year, but I do want to kick the tires with you, engage. You're confident of this being a plausible scenario given you've got some one-offs that you've enjoyed this year that won't recur next year, but you also seem to have some very strong underlying momentum across life science and electronics. Thank you.
34:22 Thank you very much, Peter. It's Ben speaking. Let me address your first two questions on electronics, one regarding price volume and the second one regarding the outlook in 2027. So when you zoom out, let me give you some context. As Kai and Helene said, we raised our organic sales growth guidance for electronics from 6% to 9% to 10% to 11%. What's driving that? It's mainly advanced node ramps across semiconductor solutions, which have developed ahead of our expectations. But we are also, to your question, seeing a temporary pricing contribution. Majority, though, is volume driven. So we're actively managing our supply chain to support our customers to ensure fair compensation for the contributions that we're making. And again, against a strong backdrop of demand, we have certain raw materials that are tight in supply and their market prices have risen significantly.
35:13 So for the full year 2026, we expect this pricing effect to contribute roughly two percentage points to organic sales growth in semiconductor solutions. And if we want to go deeper, we expect roughly one-third in Q3 and two-thirds of that to happen in Q4. As we look into the future from a pricing viewpoint, in our base case, we expect the raw materials market conditions to normalize over the course of 2027. with, again, the associated pricing support fading accordingly on this particular effect. Regarding the outlook in 2027 on the industry overall, what we are seeing and hearing from our customers, especially at the most advanced nodes and at the leading edge, capacity remains constrained and capacity remains very tight. The main driver of our growth continues to be advanced node ramps in logic, in memory, as well as in advanced packaging, which, as I said, have progressed ahead of our expectations. Our customers will be in Taiwan, Japan next week. They're working tirelessly to bring additional capacity online and remove supply bottlenecks. So that's the focus currently, and that's the outlook into 2027.
36:24 I have to say, though, as Kai mentioned, consumer electronics application segment remains very much suppressed by the high memory pricing and the focus of the industry on the AI segment in particular.
36:38 So Peter, thanks for your question. You were absolutely right that we don't guide today. Still a great question. And look, you heard me talking about solid underlying trends back in August. And that's because really nothing has changed. Market fundamentals are absolutely intact. And looking into next year requires us first to look into 2026. And we have upgraded our organic sales course guidance for the third consecutive time this year. This year underlines the strength of our portfolio. And of course, as a base effect as Q3 next year's growth outlook maybe a little bit. Our teams have done a fantastic job in managing the Mavenclass decline and ensuring supply availability in H1 when demand in process solutions experienced an extra boost. So let me repeat, we faced tough comps in PAS in H1 and this Mavenclass US sales down almost 50% sequentially in Q3. It's only fair to assume a rather steep maven class decline in 2027.
37:38 So back to the upgraded group guidance for 2026, you will see there's a bit of slowdown organically implied for Q4 and we expect this to continue into early next year. So let me zoom out. We feel absolutely confident with our midterm guidance. But as I have lined out, there are a few effects that you should take into account when thinking about organic growth in 2027. At the same time, we expect a significant boost to reported numbers of LS and the group from the recent sharpening of the portfolio and biotechnology in particular. So obviously, we will hear more from us in March 2027. We will share our quantitative guidance. And let's look into Helene. Can you add anything?
38:25 Yeah, I can actually, and I'm not going to repeat everything that you've just said, but there may be just one aspect I would like to add in terms of margins. Healthcare will see pressure from Marvinklad, and the IMD ratio may slightly increase due to, for example, silent therapeutics. Nevertheless, as said several times, we're absolutely committed to manage the healthcare EBITDA pre-margin north of 30%. And if you think about life science and electronics, we strongly believe to be able to drive margin expansion. Both could see 30% already next year. Having said this, let me comment a bit further on biotechnology in this context. Biotechnology alone will add close to 5% to group sales and about 10% to life science.
39:17 While we remain absolutely committed to EPSP accretion in year three after closing, keep in mind that both Biotechni and the announced divestiture of the US CDMO business will be immediately accretive through group and licensed EBITDA pre-margin post-closing. Thank you. Thank you. We are now going to take the next question. And this one is from Matthew Winston from UBS. Please go ahead.
39:54 Thank you for taking the questions. Two, please. I think they're probably both for Helene. Helene, Vera Therapeutics, your partner, you've made clear in the past that royalties are shared with Bristol and Zymo. We were expecting an approval milestone in 3Q, but it seems to have been absorbed in the pharma or healthcare other income line. So, can you confirm that a proportion of milestones are also passed on to Bristol and Zymo? And if so, can you give us a reasonable proportion for future modelling that Merck will keep? And then the second one, just on Biotechna. You've talked about pushes and pulls and you've been able to bring the closing of the transaction forward. I recall that you have an option to also bring forward the full consolidation of Wilson Wolf and that was an element that was going to add extra accretion to the Biotechna deal. Is there potential that that can also come early and boost accretion in 27?
40:58 So my colleagues are trumping us a bit to answer your question and hence I will hand over first to Danny.
41:08 Thanks. So Richard, when it comes to VERA, when it comes to milestones and royalties, it is fair to assume that there is a meaningful obligation from Merck to BMS. VERA disclosed a, and I quote them, low to mid teens percent royalty rate. However, you know, in virtually every scenario, the net royalty rate upside for us would remain in the single-digit percent range. Sorry, it was Matthew.
41:48 And on the milestones, Danny, is it true there as well?
42:06 I'm looking into that. We'll get back to you after... The answer to the second question.
42:12 Okay, so I can take the Wilson Wolf one. It's Q128 and there's no option to move this closing.
42:22 Okay, thank you. Matthew, regarding the milestones, it's similar proportions as I said before.
42:29 Okay, perfect. Thank you very much both. Thank you. We are now going to take the next question. and this one is from James Quigley from Goldman Sachs.
42:43 Please go ahead. Great, thank you for taking my questions. I have two, please. One on life sciences, one on healthcare. So in the life sciences, one of your competitors saw an increase in the lab division growth given or partly given by AI. They highlight the bioanalytics instrument portfolio there as well. You noted on the slides that the high-tech instruments have been recovering, mostly driven by pharma and biotech. So what are you seeing with respect to potential impact on discovering an advanced solution from all that that could be attributed to any increase in activity due to AI? And the second question for Danny on Gamecly and Oxivio. The country growth for both has slowed in the quarter. Is there any seasonality impact here? Or is there something to flag with respect that could help explain the slowdown?
43:35 How are patient identification efforts progressing for both drugs? And what are you seeing in terms of patient starts? And at what point can we start to see an inflection in the sales there? Thank you.
43:49 Hi James, Jean Charles speaking. So let me answer the first question related to the labs, business and AI. So at customer level, I would say we see no significant standing shift yet. But it's true that we saw in the market numerous of deal announcements dealing with biobucks and AI could increase the demands for experimental validation mid to long term. That said, AI and innovation are central to our Merck Last Sense strategy. And to give you some concrete examples, we are working linked to our strategy execution on AI solutions.
44:41 And let me take the opportunity to give you a concrete example. The first one is on advanced solutions. We launched Chemist Twin, which is an AI-powered digital reference materials platform for analytical control, and it drives more sustainable testing for customers. The other example is around drug discovery solutions, so both are touching the lab business, and I'm talking about Cynthia at Gunting AI, which is again an AI-powered digital chemistry solution which help our customer to successfully design a target molecule and in fact it speeds up their overall research process. So in a nutshell, to answer your question, we don't see yet in the market significant spending shifts.
45:36 However, from a strategy point of view, we are diligently working on it and I just wanted to share with you two concrete examples.
45:48 Hi James, it's Danny. Thank you for your questions regarding Oxivio and Gomekli. So let's start with Oxivio, you know, to give you a little bit more color on that. So the Q3 sales were up 24% year over year. It's growing 4% up quarter over quarter, and this is driven by higher U.S. demand, additional launches in other countries, and increased named patient sales demand. Now, I am encouraged by improving underlying demand metrics, including growth in new patient starts, high refill rates, and also low and slightly going down even discontinuations. And this gives us confidence in terms of growth in the quarters ahead. The question is can we do more?
46:42 And the answer to that is yes. We clearly believe that we can, especially when it comes to the U.S., or actually for both Oxivio and Gomecki. Now, beyond these metrics, physician adoption when you look at it remains very strong. Oxivio continues to lead all treatment options in satisfaction. Nearly all aware oncologists have prescribed it in the last 12 months. Approximately 80% of oncologists expect to increase their Oxivio usage over the next year. More than 90% now view the systemic therapy as the guideline recommended first-line approach for progressing desmoid tumors. Now, these leading indicators actually reinforce my confidence, our confidence in continued demand growth and the long-term opportunity for OXIVIO.
47:32 That's encouraging. Now, still there is a gap, as always in medicine, between awareness to, for example, avoiding surgery and We also expect commercial execution to strengthen in the fourth quarter and beyond as we now benefit from a fully deployed field organization and some recent investments to improve even further patient identification, treatment initiation, and persistence. Also, new data generation studies are underway in key geographies to provide important answers, and this will also help improve the treatment of desmoid tumor patients. Now, there is one more important thing that I would like to mention, and this relates to both products. We are picking up very nicely XUS, and in fact, in the next year, we are going to launch in about 15, one-five countries. and the experience in some countries in Europe, also outside of Europe, like Saudi, like Emirates, has been super positive.
48:53 And I guess that you know, in rare diseases, one should not always expect two-thirds of higher of the revenue coming from the US. Now, a couple of words on Gomekli. There are some similarities to the market situation with Exivio, but don't treat it as one-to-one. Q3 increased 80% for Gomecki year over year, driven primarily by continued, again, demand in the U.S., in addition to patient uptake, also in Germany, and named patient sales, which is encouraging. And the sequential growth in Q3 is supported by solid, very solid underlying patient dynamics. New patient starts increased more than 20% compared with the previous quarter.
49:41 with actually September being one of the strongest months since launch. We're also encouraged by patient persistence, reflecting both the product's tolerability profile, which we knew it would be great, and our ongoing patient support initiatives, which we are very strong at. Now, turning to competitive dynamics, as you know, for Gometli we have already competition, which has been in the market for more than five years. I'm actually very pleased with our positioning in both the adult and the pediatric segments. Adults now represent approximately 70% of our treatment volume. We were the first approved treatments for adult NF1 PN in the U.S. and Gomecli has established itself, clearly established itself as the leading brand for new adult patient starts.
50:32 And we also continue to build adoption in PEDS, supported by our I would say differentiated clinical profiles, tolerability and convenience. Same potential for expansion and same continued efforts that will bring us to the, I would say to the promised plans, although it will take more time for both products.
50:59 Excellent, thank you. Thank you. We are now going to take the next question. And this one is from Simon Baker from Rothschild and Cole Redburn. Please go ahead.
51:14 Thank you very much for taking my questions. Two, if I may, please. Firstly, on the life science guidance increase, given the narrowing of the range, the increase at the bottom rather than the top end because of the biotechnology inclusion, I just wondered if there were any other pushes and pulls beyond biotechnology within that, or it's simply a narrowing of the range as we are three quarters through the year? and then secondly a question for Danny on Silence Therapeutics and clearly the deal was driven by Diversa RAN but I just wondered if you could talk about the opportunities as you see them beyond Diversa RAN and a few other things in the portfolio and particularly Xelatherin in light of the Pellicarsen Horizon data. Thanks so much.
52:06 So let me take the first one. and it will be a short answer. I mean, biotechnology will be treated as portfolio effect. So biotechnology will have no impact on our organic growth.
52:25 Regarding silence, yes, of course, we're super excited with diverse Iran, very strong phase two data that point to actually tick many boxes in what we told you in previous months. homogeneous populations, rare diseases, phase 2 endpoints that de-risk phase 3. So we're super excited about the potential. To your question regarding the LP little a, you saw the recent presentation of of the Novartis drug. It's super disappointing. The drug clearly does pharmacodynamically what it is supposed to do, but clinically not a lot, I would say. So from our perspective, the LpA project is not something that we will continue pursuing.
53:22 Thanks so much. Thank you. We are now going to take the next question. And this one is from Thibault Bouserin from Morgan Stanley. Please go ahead.
53:37 Yes, thank you very much. One question on electronics. If you could give us some colors on the trends in the delivery services in the quarter. Has it been a meaningful contributor? Was there a change in trend? And do you have visibility into Q4 and how we should think about it in 27? and then just a clarification on the BTS phasing you mentioned and Q4 growth being meeting a digit. Can you confirm that this phasing means, you know, strong 9 months, first 9 months of the year and positive phasing in first 9 months leading to negative phasing in Q4 or is it phasing into next year? Thank you.
54:20 Hey Thibault, thank you very much for your question. It's Ben speaking. Appreciate you. So regarding DSS, let me give you some color. Overall delivery systems and services is growing, but it was diluted to electronics growth in Q3. Just as a reminder, DSS accounts for less than 15% of the overall electronics business. So given its relative small base, the timing of large projects that, again, we're executing right now can swing it quite easily within quarters. and large projects were again the main driver this particular quarter. We take on new projects only very selectively when they make economic sense for us so we don't include them into our base. What is encouraging though is that equipment has been recovering.
55:08 Remember last quarter we committed that DS&S will be stabilizing and it's actually the equipment parts recovering quite nicely since the traffic at the end of last year. which should make DSMS overall less dependent on the large project business over time. But the key growth driver of semiconductor solution remains the semiconductor materials business which again is fueled by AI and also the advanced nodes. And we've been seeing the 11th consecutive quarter of year-over-year growth in semiconductor materials with an average of low teens.
55:45 Hi Thibault, Jean Charles speaking. So let me clarify and answer your question on process solution. So more than anything else, we are talking about phasing effect from Q3 to Q4. So what does it mean? It means that when you look the full year, we are very confident. I am very confident that the performance of process solution will be in the higher range Thank you very much. and we are marching towards a very strong performance this year.
57:00 Thank you. We are now going to take the next question. And this one comes from Charles Pittman King from Barclays. Please go ahead.
57:13 Hi guys thanks very much for taking my questions two from me please firstly just on EPS into next year noting the raised tax guidance guided biotechnology UPS solution and the science therapeutics versus long as the CDMO sale impact on their financials as well as Maving Thad's erosion from 3T next year. Just wondering if you can confirm whether the margin expansion from lifestyle and electronics will enable you to grow your EPS next year. And then maybe secondly on process solutions in terms of the order, but can you just remind us on the typical lead time for your assets given Merck's primarily exposed to the consumable side of the lifestyle market. should imply a shorter lead time, and what that then implies for the strength of visibility you have on the durability of this order trend, just effectively this expectation of a declining order trend in FY27, certain are you of this?
58:14 Okay, so again, it's a bit hard without giving you guidance to talk about EPS, but I can give you a bit of push and pulls if that's helpful. Number one, as you've seen, we've hedged biotechnology interest rates. That will be an important input factor. Number two, we were very clear on healthcare that we will retain above the 30% margin. As I already said earlier, we're also looking pretty confident that we will be able to have that 30% margin in life science and electronics. So I think with that, you get most of the parameters to put the model together. And yeah, more to come next earnings call.
58:54 Hey Charles, Jean Charles speaking. So to your second question concerning the PS lead time and visibility, I mentioned several times that learning from the past, we have been able to rebuild our business trend history by region, by customer, by product order type. and back to 2018. So we have more or less eight years of history and I will say we are back to normal lead time now for a few quarters and the average lead time is in the range of call it one to six months for process solution.
59:35 Madalena, we have time for one last question. That Thank you. The last question comes from the line of Oliver Mascaire from AutoBHF. Please go ahead.
59:53 Yeah, good afternoon. Thanks for squeezing me in. The first question is on discovery solutions. So we see, well, I would say more muted development already for some time. You mentioned in your slides biology as growth driver, also academia stabilizing. So I'm sure you won't give the guidance for next year, but it would be great to hear some of your thoughts about the normalization over the next quarters. And my second question is also a follow-up on Octavio and Gumegli, because you already gave a hint that it doesn't make sense that the U.S. accounts for two-thirds. Can you remind us about the patient potential of a market outside the U.S.?
1:00:43 Thank you.
1:00:47 So, let me start with Discovery Solutions. So, very high level. Discovery Solutions, we have two franchises within this business, BioG and Chemistry. We are also leveraging our multi-channel approach, meaning leveraging on our dealers, our beautiful e-commerce platform, our sales specialists, sales generally. And I will say, overall, in the current market dynamic, we are seeing, it's true, stabilization around academia. We are also seeing kind of normalization across customer segments and regions. So, in a nutshell, Thinking about discovery solution, we should assume low single digit organic growth for this business. And again, I'm talking low single digits without thinking about biotechnology acquisition.
1:01:51 Thanks JC. Oliver, so look regarding the market potential of the patient numbers. for Obsidio and Gomecki outside of the U.S. So when we communicated the deal, we spoke in terms of desmoid tumor, for example, for a potential of around 20,000 patients. But as I said a couple of minutes ago, building that market and changing referrals and physicians' behaviors The same magnitude of numbers you can think about also for when it comes to NF1PN, adult versus pediatric, adults plus pediatric also in Europe. You can think about the same numbers.
1:02:49 Here I would say in adults inside and outside of the U.S., the potential is higher. because many of these adults that are not treated do not usually visit centers of excellence like KID. But here I want to say something else. When we communicated the deal, we clearly said that one of the key value drivers is the global expansion for both products. And as I said a couple of minutes ago, you should expect the contribution of ex-US to be quite significant here. That's helpful, thank you. Thank you Ladies and gentlemen, thank you for your attendance.
1:03:58 This call has been concluded. You may disconnect.
Follow Merck KGaA into a list and get an email when it puts out news.
Analyst, Goldman Sachs
Analyst, J.P. Morgan
Analyst, Rothschild & Co Redburn
Analyst, UBS
Analyst, Barclays
Analyst, BNP Paribas
Group CFO, Merck
Analyst, ODDO BHF
CEO Life Science, Merck
CEO Electronics, Merck
Group CEO, Merck
CEO Healthcare, Merck
Head of Investor Relations, Merck
Analyst, Morgan Stanley